Comments on: Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

Comments on: Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins) https://9krapalm.com/dizal-announces-positive-topline-phase-3-results-from-wu-kong28-study-evaluating-oral-once-daily-zegfrovy-sunvozertinib-vs-platinum-containing-chemo-doublet-in-first-line-non-small-cell-lun/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Sat, 21 Mar 2026 11:43:53 +0000 hourly 1 https://wordpress.org/?v=7.0